IMV Advances Phase 1b/2 Trial of DPX-Survivac Following Positive Feedback from FDA
News
IMV has completed an amendment to the protocol of its Phase 1/2 clinical trial testing a triple combination of DPX-Survivac, epacadostat, and low-dose chemotherapy in recurrent ovarian cancer. The company now ... Read more